Alejandro Treszezamsky, MD
Urogynecology and Reconstructive Pelvic Surgery · San Antonio, TXNPI 1164681987
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (59.8%), food and beverage and education — rather than concentrated in one kind of arrangement. Axonics, Inc. accounts for 68.1% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2021 at $1,489 and has fallen 92.6% since, to $110 in 2025. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in TX, where the typical reported total is $5,014.
Across 15 payments — averaging $134.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axonics, Inc.$1K
- Caldera Medical, Inc$256
- Coloplast$135
- Femselect Inc.$131
- Astellas Pharma US Inc$80
- Boston Scientific$39
What the payments were for
- Travel & lodging$1,20460%
- Food & beverage$72836%
- Education$804%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axonics, Inc. | 5 | $1,370 |
| Caldera Medical, Inc | 5 | $256 |
| Coloplast | 2 | $135 |
| Femselect Inc. | 1 | $131 |
| Astellas Pharma US Inc | 1 | $80 |
| Boston Scientific | 1 | $39 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axonics r-SNM System$1,204
- Bulkamid$1,204
- EnPlace$131
- Desara$116
- RESTORELLE$110
How this compares
$2,012 in reported general payments places this provider in the 20th percentile of 74 urogynecology and reconstructive pelvic surgery providers in Texas.
See all urogynecology and reconstructive pelvic surgery providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 204 | $132,121 |
| GemtesaVibegron | 110 | $78,387 |
| Mirabegron ErMirabegron | 34 | $16,332 |
| Estradiol | 119 | $8,891 |
| Metronidazole | 76 | $3,108 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 197 | $2,736 |
| Oxybutynin Chloride ErOxybutynin Chloride | 130 | $1,783 |
| Solifenacin Succinate | 24 | $1,230 |
| Fluconazole | 56 | $653 |
| Darifenacin ErDarifenacin Hydrobromide | 11 | $489 |
| Methenamine Hippurate | 11 | $475 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 17 | $324 |
| Tramadol Hcl | 129 | $249 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 104 | $221 |
| Cephalexin | 21 | $203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $80 | $132,121204 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 74 urogynecology and reconstructive pelvic surgery providers in Texas.
Other urogynecology and reconstructive pelvic surgery in San Antonio
- Stephen KrausSan Antonio$372K
- Vaneesha Vallabh-PatelSan Antonio$13K
- Ebenezer BabalolaSan Antonio$3K
- Elizabeth EvansSan Antonio$3K
- Lina LozaSan Antonio$2K
- Keith XavierArlington$282K
- Tomas AntoniniAustin$183K
- Amanda WhiteAustin$108K
- Gazala SiddiquiHouston$81K
- Fiona LindoHouston$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.